CD34 expression in low-grade epilepsy-associated tumors: relationships with clinicopathological features

Marco Giulioni, Gianluca Marucci, Massimo Cossu, Laura Tassi, Manuela Bramerio, Carmen Barba, Anna Maria Buccoliero, Gianfranco Vornetti, Corrado Zenesini, Alessandro Consales, Luca De Palma, Flavio Villani, Giancarlo Di Gennaro, Giampaolo Vatti, Nelia Zamponi, Gabriella Colicchio, Carlo Efisio Marras

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.

METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.

RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.

CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.

Original languageEnglish
Number of pages8
JournalWorld Neurosurgery
DOIs
Publication statusE-pub ahead of print - Oct 8 2018

Fingerprint

Epilepsy
Neoplasms
Multivariate Analysis
Odds Ratio
Ganglioglioma
Neuroepithelial Neoplasms
Central Nervous System Neoplasms
Histology
Retrospective Studies
Demography

Cite this

CD34 expression in low-grade epilepsy-associated tumors : relationships with clinicopathological features. / Giulioni, Marco; Marucci, Gianluca; Cossu, Massimo; Tassi, Laura; Bramerio, Manuela; Barba, Carmen; Buccoliero, Anna Maria; Vornetti, Gianfranco; Zenesini, Corrado; Consales, Alessandro; De Palma, Luca; Villani, Flavio; Di Gennaro, Giancarlo; Vatti, Giampaolo; Zamponi, Nelia; Colicchio, Gabriella; Marras, Carlo Efisio.

In: World Neurosurgery, 08.10.2018.

Research output: Contribution to journalArticle

Giulioni, Marco ; Marucci, Gianluca ; Cossu, Massimo ; Tassi, Laura ; Bramerio, Manuela ; Barba, Carmen ; Buccoliero, Anna Maria ; Vornetti, Gianfranco ; Zenesini, Corrado ; Consales, Alessandro ; De Palma, Luca ; Villani, Flavio ; Di Gennaro, Giancarlo ; Vatti, Giampaolo ; Zamponi, Nelia ; Colicchio, Gabriella ; Marras, Carlo Efisio. / CD34 expression in low-grade epilepsy-associated tumors : relationships with clinicopathological features. In: World Neurosurgery. 2018.
@article{06e7facf807544f68e46024addff37a1,
title = "CD34 expression in low-grade epilepsy-associated tumors: relationships with clinicopathological features",
abstract = "OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.RESULTS: Ninety-five (50.8{\%}) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.",
author = "Marco Giulioni and Gianluca Marucci and Massimo Cossu and Laura Tassi and Manuela Bramerio and Carmen Barba and Buccoliero, {Anna Maria} and Gianfranco Vornetti and Corrado Zenesini and Alessandro Consales and {De Palma}, Luca and Flavio Villani and {Di Gennaro}, Giancarlo and Giampaolo Vatti and Nelia Zamponi and Gabriella Colicchio and Marras, {Carlo Efisio}",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
month = "10",
day = "8",
doi = "10.1016/j.wneu.2018.09.212",
language = "English",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - CD34 expression in low-grade epilepsy-associated tumors

T2 - relationships with clinicopathological features

AU - Giulioni, Marco

AU - Marucci, Gianluca

AU - Cossu, Massimo

AU - Tassi, Laura

AU - Bramerio, Manuela

AU - Barba, Carmen

AU - Buccoliero, Anna Maria

AU - Vornetti, Gianfranco

AU - Zenesini, Corrado

AU - Consales, Alessandro

AU - De Palma, Luca

AU - Villani, Flavio

AU - Di Gennaro, Giancarlo

AU - Vatti, Giampaolo

AU - Zamponi, Nelia

AU - Colicchio, Gabriella

AU - Marras, Carlo Efisio

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018/10/8

Y1 - 2018/10/8

N2 - OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.

AB - OBJECTIVE: To analyze the relationships between CD34 expression and several demographic, clinical and pathological features, in patients with histopathological evidence of low-grade epilepsy-associated tumors (LEATs) who underwent epilepsy surgery.METHODS: We conducted a retrospective study enrolling 187 patients with LEATs who underwent surgery between January 2009 and June 2015 at eight Italian epilepsy surgery centers. All cases were histologically diagnosed according to the WHO classification of tumors of the central nervous system. Univariate and multivariate analyses were performed to identify variables associated with CD34 expression.RESULTS: Ninety-five (50.8%) out of 187 patients were CD34 positive. At multivariate analysis, tumor type and duration of epilepsy were independently associated with CD34 expression. Ganglioglioma and pleomorphic xanthoastrocytoma were the histotypes with the strongest association with CD34 positivity, with an odds ratio (OR) of 9.2 and 10.4 respectively, compared to dysembryoplastic neuroepithelial tumors. Patients with a duration of epilepsy longer than 10 years had significantly higher chances to show CD34 expression, with an OR of 2.8 compared to those with a duration of epilepsy shorter than 2 years. Furthermore, at univariate analysis CD34 expression appeared significantly related to older age at surgery, higher AEDs intake, and female gender.CONCLUSIONS: Our study suggests that CD34 expression holds promise as a useful biomolecular marker for LEATs patients, with evidence of a link with clinicopathological features. We confirmed the association between CD34 expression and tumor type and demonstrated a significantly higher probability of CD34 expression in patients with a longer duration of epilepsy, independently of histology.

U2 - 10.1016/j.wneu.2018.09.212

DO - 10.1016/j.wneu.2018.09.212

M3 - Article

C2 - 30308344

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -